ABCL ▲ +2.3% - AbCellera Biologics Inc. $ABCL AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 AbCellera rose 2.3% following the company's announcement that it will present Phase 2 data for its menopause treatment candidate ABCL635 at the IMS World Congress on Menopause 2026, signaling progress in the clinical development of the asset. 16-SEP-2026 04:05 PM ET